The timing reflects a documented surge in AI patent filings. USPTO applications have risen 33 percent since 2018, with AI representing 60 percent of technology subclasses by 2023. The World Intellectual Property Organization reported that 25 percent of generative AI patent families were published in 2023 alone. Major pharmaceutical and technology companies—including Roche, which filed 72 AI patents in the first quarter of 2024 for digital pathology and protein design, along with NVIDIA, LG Electronics, Intel, and Cilag—are actively building AI patent portfolios. The specific contours of how these companies are deploying AI across their patent lifecycles remain incompletely documented in public filings.
Patent counsel should monitor how the USPTO's pro-AI stance influences prosecution outcomes and claim construction in litigation. With the global AI patent market projected to grow from $309.53 billion to $2.49 trillion by 2034, competitive pressure to file broadly and quickly will intensify. Practitioners handling life sciences transactions and due diligence should expect heightened scrutiny around inventorship documentation and the delineation between AI-assisted and AI-generated work—issues that remain unsettled in case law and USPTO practice despite recent guidance shifts.